ABOS Stock Summary and Trading Ideas (Acumen Pharmaceuticals | NASDAQ:ABOS)

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.

Acumen Pharmaceuticals trades on the NASDAQ stock market under the symbol ABOS.

As of June 9, 2026, ABOS stock price climbed to $2.19 with 312,112 million shares trading.

ABOS has a beta of 1.94, meaning it tends to be more sensitive to market movements. ABOS has a correlation of 0.08 to the broad based SPY ETF.

ABOS has a market cap of $158.15 million. This is considered a Micro Cap stock.

In the last 3 years, ABOS traded as high as $11.31 and as low as $.86.

The top ETF exchange traded funds that ABOS belongs to (by Net Assets): VTI, VXF, DFAS, IWC, DFMC.

ABOS has outperformed the market in the last year with a return of +72.4%, while the SPY ETF gained +24.1%. However, in the most recent history, ABOS shares have underperformed the stock market with its stock returning -30.3% in the last 3 month period and -9.5% for the last 2 week period, while SPY has returned +8.9% and -1.8%, respectively.

ABOS support price is $2.07 and resistance is $2.27 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABOS shares will trade within this expected range on the day.